We found that while low-dose TSA and PD-L1 blockade each inhibited tumor growth and increased survival (Fig. 6b, c and Supplementary Fig. 7f), low-dose TSA and PD-L1 antibody in combination further reduced tumor growth and prolonged the overall survival compared to monotherapy groups in syngeneic mouse models (Fig. 6b, c and Supplementary Fig. 7f). The gene discussed is CD274; the disease is neoplasm.